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Neuromuscular exercise and pain
neuroscience education compared with
pain neuroscience education alone in
patients with chronic pain after primary
total knee arthroplasty: study protocol for
the NEPNEP randomized controlled trial
Jesper Bie Larsen1,2* , Søren T. Skou3,4, Lars Arendt-Nielsen1, Ole Simonsen5 and Pascal Madeleine2
Abstract
Background: Total knee arthroplasty (TKA) is considered an effective treatment for pain relief and improved
physical performances in end-stage knee osteoarthritis. However, several studies have reported less favorable
outcomes after TKA with chronic pain rates of approximately 20%. Exercise might be an effective treatment strategy
for chronic pain following TKA, but no randomized controlled trials have evaluated its effect. Therefore, the purpose
of this randomized controlled trial is to investigate whether a 12-week neuromuscular exercise (NEuroMuscular
EXercise training program for patients with knee or hip osteoarthritis assigned for total joint replacement; NEMEX-
TJR) program combined with pain neuroscience education (PNE) provides greater pain relief and improvement in
physical performances than PNE alone at 12 months follow-up in a population of patients with chronic pain after
primary TKA.
Methods: For this randomized controlled superiority trial, 120 patients with moderate-to-severe chronic pain after
TKA are recruited from Aalborg University Hospital, Denmark. Patients are randomly assigned in a 1:1 ratio to one of
two interventions: (a) NEMEX-TJR twice weekly for 12 weeks combined with two sessions of PNE or (b) two sessions
of PNE given over 6 weeks. Assessment is performed at baseline before intervention and at 3, 6, and 12 months
after initiation of the intervention. Outcome assessors are blinded toward group allocation. The primary outcome is
the change in the Knee Injury and Osteoarthritis Outcome Score4 (KOOS4), defined as the mean score for the KOOS
subscales pain, symptoms, activities of daily living, and quality of life. Secondary outcomes include all KOOS
subscale scores and scores for PainDETECT, the Fear-Avoidance Beliefs Questionnaire, Global Perceived Effect, the
Pain Catastrophizing Scale, pain intensities, temporal summation, conditioned pain modulation, and pressure pain
thresholds. Physical performances are measured with walking, stair climbing, and chair standing tests as well as
tests of muscle strength and power.
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© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: jbl@hst.aau.dk
1Translational Pain Biomarker, SMI, Department of Health Science and
Technology, School of Medicine, Aalborg University, Aalborg, Denmark
2Sports Sciences – Performance and Technology, Department of Health
Science and Technology, School of Medicine, Aalborg University, Aalborg,
Denmark
Full list of author information is available at the end of the article
Larsen et al. Trials          (2020) 21:218 
https://doi.org/10.1186/s13063-020-4126-5
(Continued from previous page)
Discussion: The findings will be useful in establishing effective treatment strategies for chronic pain after TKA. The
randomized controlled trial involves rigorous scientific methods and uses clinically applicable interventions. The
study interventions are conducted in clinical settings, thereby enhancing the possibility of future implementation of
the treatments in the health care systems.
Trial registration: ClinicalTrials.gov identifier: NCT03886259. Registered 22 March 2019. Ethics committee
registration: N-20180046.
Keywords: Total knee replacement, Chronic pain, Neuromuscular exercise, Pain neuroscience education
Background
Osteoarthritis (OA) is considered the most frequent cause
of disability and pain in the elderly population, and the
knee joint is one of the joints most commonly affected [1,
2]. End-stage knee OA is often treated with a knee re-
placement. Total knee arthroplasty (TKA) is considered
an effective treatment for pain relief and improved phys-
ical performance [3, 4]. However, less favorable outcomes
such as chronic pain have been reported in approximately
20% of patients undergoing TKA [5]. Chronic pain in OA
patients is believed to occur as a result of local patho-
logical processes in and around the joint, genetic and
metabolic factors and neuronal changes at several levels,
including peripheral or central sensitization, reduced de-
scending inhibition, and atrophy of cortical areas [6].
These mechanisms are considered important for the de-
velopment of chronic pain after TKA [7, 8].
A systematic review reported that 20% of patients felt
that TKA surgery had not been successful enough to
resume their regular activities of daily living (ADL), in-
cluding walking, stair climbing, dressing, and getting in
and out of bed [9]. Therefore, the rehabilitation of pa-
tients with chronic pain after TKA needs to aim for both
reducing pain and improving physical performance.
Guidelines for knee OA have established exercise as an
effective treatment for both pain and functional impair-
ment [10, 11]. For patients suffering from chronic pain
after TKA, no such guidelines or standardized treatment
regime exist. This is emphasized in two recent systematic
reviews, summarizing the evidence regarding the treat-
ment of chronic pain after TKA and reporting the absence
of randomized controlled trials evaluating the effects of
exercise therapy and other treatments [12, 13].
A neuromuscular exercise (NEuroMuscular EXercise
training program for patients with knee or hip osteoarthritis
assigned for total joint replacement; NEMEX-TJR) program
developed by Ageberg et al. (2010) has been shown to be
feasible and effective in treating pain and impaired function
in patients with end-stage knee OA and immediately fol-
lowing TKA surgery [14, 15]. The NEMEX-TJR program
aims at improving sensorimotor control and functional
joint stability by using weight-bearing exercises with a focus
on the quality and alignment of movements, optimal
activation and loading of muscles, and postural control
[14, 16]. Such a focus could also be relevant for patients
with chronic pain after TKA. However, it is unknown
whether the NEMEX-TJR program or any other exercise
program is effective in a population of patients with
chronic pain and impaired physical performance after
TKA, highlighting the need for high-quality clinical trials.
Over the last few years, a shift in patient information
from the biomedical model to a biopsychosocial model has
been proposed as education for chronic pain patients [17,
18]. Since sensitization is a frequent phenomenon in
chronic pain patients, a new approach to education is
needed – one that targets pain neuroscience instead of fo-
cusing on the nociceptive pain [17]. Pain neuroscience edu-
cation (PNE) has the potential to decrease anxiety and fear
of movement after surgery and could therefore be useful
for patients experiencing chronic pain after TKA [19]. Pain
neuroscience education seems to provide the best results
when delivered in conjunction with exercises, as these two
treatments modalities might optimize each other [20].
We initiated the NEPNEP (Neuromuscular Exercises and
Pain Neuroscience Education for chronic Pain) trial with
the purpose of evaluating whether a 12-week NEMEX-TJR
program combined with PNE provides greater pain relief
and improvement in physical performances than PNE alone
in a population of patients with chronic pain after primary
TKA. We hypothesize that NEMEX-TJR and PNE in com-
bination can provide greater pain relief and better physical
performance compared to PNE alone after 12months.
Methods/design
Study design
This study is a randomized controlled superiority trial
with blinding of both the outcome assessor and the
statistician analyzing the data. This study protocol fol-
lows the recommendations of the SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) guideline [21] (see supplementary file 1). In con-
junction with the SPIRIT guideline, specific interven-
tions were described based on the TIDieR (Template for
Intervention Description and Replication) checklist [22]
and the CERT (Consensus on Exercise Reporting Tem-
plate) checklist [23] (see supplementary file 2).
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Ethical considerations
The trial is being conducted in accordance with the
Helsinki Declaration, has been approved by the local
ethics committee (the North Denmark Region Commit-
tee on Health Research Ethics, Aalborg, N-20180046),
and is registered at ClinicalTrials.gov (NCT03886259;
https://clinicaltrials.gov/ct2/show/NCT03886259). Any
changes to the trial protocol will be communicated to
the ethics committee and the clinical trial registry. All
patients will be thoroughly informed about the trial be-
fore inclusion and will sign informed consent forms be-
fore participation. The NEMEX-TJR program used in
the current trial has been found to be feasible and safe
to use [14]. No adverse events, besides possible tempor-
ary soreness after the NEMEX-TJR program, are ex-
pected and therefore, no data monitoring committee
has been established. If any serious adverse events
occur during the trial, these will be reported to the
North Denmark Region Committee on Health Research
Ethics, Aalborg as soon as the principal investigator has
been alerted.
Participants and settings
A total of 120 patients will be recruited from the ortho-
pedic surgical department at Aalborg University Hos-
pital. Patients will be recruited from the hospital's
patient research database and from screening patients
referred to the involved orthopedic departments. To fa-
cilitate patient enrollment it will be possible to partici-
pate at one of the three local Departments of
Occupational and Physiotherapy from the northern re-
gion of Denmark, thereby covering a larger geographical
area. Patients will have their travel expenses reimbursed
to avoid social inequality and increase adherence. Pa-
tients will be randomly assigned in a 1:1 ratio to undergo
either 12 weeks of NEMEX-TJR combined with PNE or
PNE alone. A flow diagram is presented in Fig. 1.
Fig. 1 Flow diagram
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Patients will be eligible for inclusion if they meet the
following criteria:
 male or female aged 40 to 80 years;
 body mass index (BMI) between 19 and 40 kg/m2;
 primary TKA due to OA ≥ 12 months
postoperatively;
 for the index knee, a duration of knee pain > 6
months; and
 for the index knee, an average daily pain score ≥ 4
(moderate-to-severe pain) on a numeric rating scale
(NRS; 0 (no pain) to 10 (maximum pain)) over the
last week prior to recruitment.
Patients having the following attributes will be ex-
cluded from the trial:
 chronic pain due to loosening of implant or
prosthesis failure requiring revision surgery;
 secondary causes of arthritis to the knee, such as
rheumatoid arthritis or sequelae from previous
accidents;
 surgery (including arthroscopy) of the index knee
within 3 months prior to recruitment;
 injury to the index knee within 12 months prior to
visit;
 acute pain, other than in the index knee, affecting
the lower limb and/or trunk at the time of baseline
testing;
 participation in other pain trials 2 weeks prior to
recruitment;
 pregnancy;
 drug and alcohol abuse;
 rheumatoid arthritis, neurologic illnesses or primary
pain area other than knee (e.g. low back pain or
upper extremity pain); or
 lack of ability to adhere to protocol.
Sample size
Based on the literature, a minimal clinically important dif-
ference of 10 points in the Knee injury and Osteoarthritis
Outcome Score (KOOS) is commonly used [24]. The sam-
ple size calculation was based on the KOOS4 and defined
as the mean score for the KOOS subscales of pain, symp-
toms, ADL, and quality of life. A sample size calculation
was conducted to obtain a study power of 90% to detect a
minimum improvement of 10 points on the KOOS4 in the
NEMEX-TJR and PNE group compared with the PNE
group (with a standard deviation [SD] of 15) [15, 25]. A
two-sided significance level at 0.05 was applied. The calcu-
lation revealed that 49 patients will be required in each
group. To account for possible missing data and a 20%
loss from patients missing follow-ups, a total of 60 pa-
tients will be included in each group.
Randomization and allocation concealment
The patients will be randomized in a 1:1 ratio to one of
two treatment arms: (1) NEMEX-TJR and PNE or (2)
PNE alone. Using computer-generated random numbers
in permuted blocks of four to eight patients, the project
manager will randomly assign patients to either of the
treatment arms after the informed consent has been
signed and the baseline assessment conducted.
Interventions
Patients will participate in the interventions at the local
Departments of Occupational and Physiotherapy in the
northern region of Denmark. These departments are
part of the Aalborg University Hospital, Denmark.
Patients in the exercise and PNE group will receive a 12-
week rehabilitation program consisting of the NEMEX-
TJR program [14]. The NEMEX-TJR program will be
conducted as a 1-hour, group-based session twice a week
for 12 weeks (24 sessions in all). Physiotherapists specific-
ally trained to conduct the intervention will instruct and
supervise the patients during the neuromuscular exercises,
including individualization of the load and exercise diffi-
culty based on each patient’s physical ability and pain in-
tensity. Exercises will be initiated by a warm-up session
consisting of 10minutes of ergometer cycling at a self-
selected intensity, followed by a circuit program consisting
of exercises such as pelvic lifts, sit-ups, sliding exercises,
lunges, rubber band exercises, chair stands, and stair climb-
ing, with walking as a cool-down exercise. Exercises will be
performed in two to three sets of 10 to 15 repetitions, with
a short rest between each set and exercise. Exercises will
be initiated at level 1 and could progress to levels 2 and 3.
Progression (e.g. increasing the load or range of movement
or changing the support surface) will be applied if the exer-
cises are performed with high-quality and sensorimotor
control based on visual inspection by the physiotherapist
and if patients perceive the exercises as requiring minimal
effort [14]. Pain intensity during and after training will be
monitored. Due to the chronicity of the patients’ pain, a
time-contingent approach to the exercises is preferred over
a symptom-contingent method [26]. If a major flare-up in
pain levels is experienced, the intensity and volume of
training will be reduced until symptoms are “as usual” [14].
Both treatments groups will receive the same PNE
consisting of two group-based educational sessions: one
at the start of the trial period and one 6 weeks after the
initiation of the trial. Both sessions will take 1 hour and
be conducted by a physiotherapist trained in PNE. The
sessions cover topics concerning the multifactorial na-
ture of chronic pain, sensitization, hyperalgesia, allody-
nia, and plasticity of the brain, aiming at giving patients
a better understanding of their chronic pain and thereby
engaging the patients in the treatment. Information leaf-
lets summing up the PNE topics will be handed out to
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the patients after the PNE sessions. During the sessions,
it will be possible to ask questions and share experiences
within the patient group.
Assessments and blinding
Baseline measurements will be completed prior to
randomization and follow-up measurements will be
conducted at 3, 6, and 12 months after initiation of the
intervention. All assessment will take place at the De-
partment of Occupational and Physiotherapy, Aalborg
University Hospital, Denmark (see Fig. 2). Trained out-
come assessors, blinded toward treatment allocation,
will perform all assessments. Before the follow-up as-
sessments, patients will be asked not to mention which
treatment group they have been assigned to in order to
maintain blinding. Demographic measures include gen-
der, age, height, body mass, BMI, index knee, dominant
leg, time since surgery, comorbidities, and scores on
the Hospital Anxiety and Depression Scale [27].
Outcomes
Primary outcome
Knee Injury and Osteoarthritis Outcome Score4
(KOOS4) The primary outcome will be the change from
baseline to 12 months in KOOS4, which will be an
average of the four subscales of pain, symptoms, ADL,
and quality of life from the patient-reported outcome
measure KOOS. The KOOS4 ranges from 0 (worst) to
100 (best) [24]. A minimum change of 10 points is
considered clinically relevant [25].
Secondary outcomes
Patient-reported outcome measures Several patient-
reported outcome measures will be collected (Fig. 2).
The scores on all five KOOS subscales, including the
sport-recreation subscale, will be included to support
the clinical interpretation of the primary outcome [28].
The PainDETECT questionnaire is a screening tool that
predicts the likelihood of a neuropathic pain component
in chronic pain disorders [29]. The Fear-Avoidance Be-
liefs Questionnaire – Physical Activity is a four-item
questionnaire for which a high score indicates a high de-
gree of fear-avoidance beliefs [30, 31]. Global perceived
effect will be assessed using the question: “How are your
knee problems now compared with before you entered
this study?” The question will be answered on a 7-point
Likert scale ranging from “improved, an important im-
provement” to “worse, an important worsening” [32].
The Pain Catastrophizing Scale is a 13-item question-
naire developed to explore how catastrophizing affects
pain experiences [33].
Pain-related outcome measures Pain intensity ratings
will be measured using NRS for the average daily pain
intensity over the last week prior to the visit and the
maximal pain intensity during rest (day and night), walk-
ing, and stair climbing. Patients will also be asked to
draw their habitual pain distribution on anatomical body
maps [34]. A handheld algometer (Somedic, Hörby,
Sweden) with a 1-cm2 probe will be used to record the
pressure pain threshold (PPT) in kPa, which can be reli-
ably assessed using pressure algometry [35, 36]. The
pressure will be increased gradually at a rate of 30 kPa/s
until the pain threshold is reached and the patient
presses a stop button. The PPTs will be measured three
times for each point with an interval of a minimum of
20 seconds between each PPT assessment. The average
of the three PPTs will be calculated for further analysis.
Bedside tests for sensitization consist of pinprick hyper-
algesia, temporal summation, dynamic mechanic allody-
nia, and deep somatic hyperalgesia. A single pinprick
with a nylon filament (0.7 mm, Chicago Medical Supply)
will be applied perpendicularly to the skin (until slight
bending of the filament occurs, when a force of 75 gram is
applied) and the patients rated the pain intensity on an
NRS. Temporal summation will be measured using the
nylon filament (0.7mm) applied 10 times in an area of 1
cm2 with a frequency of 1/s. Then, the patients will rate
the intensity of the last stimulus on an NRS. Dynamic
mechanical allodynia will be examined using a cotton
swab stroked four times on the skin (twice from each
direction of a cross with 90° angles). The length of each
stroke will be 3–5 cm. The patients will rate the pain in-
tensity induced by the stroke on an NRS. Deep somatic
hyperalgesia will be measured using a bedside pressure
algometer (syringe). The air in the syringe will be com-
pressed at a constant speed (1ml/s) until the pressure be-
comes painful. The patients will be asked to indicate when
the pressure became painful (threshold in ml). Pressure
pain thresholds and bedside tests for sensitization will be
recorded in the area of the index knee, adjacent to the
knee (10 cm above the knee, ventral thigh), and extra-
segmentally on the medial side of the forearm (muscle
belly of the flexor digitorum superficialis). Conditioned
pain modulation will be assessed using PPT as test stimuli
and a spring-based pressure clamp applying a force of 1.3
kg as conditioning stimuli. Test stimuli will be applied to
the middle part of the tibialis anterior muscle of the non-
affected side and conditioning stimuli will be applied to
the ipsilateral earlobe. The patients will be asked to report
their use of pain medication during last week (yes/no), in-
cluding the number of paracetamols (1 g), ibuprofen (400
mg), and other nonsteroidal anti-inflammatory drugs.
Physical performance measures Five objective physical
performance measures will be collected (Fig. 2). Based
on the Osteoarthritis Research Society Internationals
core recommendations for physical performance
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Fig. 2 SPIRIT figure showing schedule of enrolment, interventions, and trial outcomes to be assessed
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measures, a 40-meter fast-paced walk test, a stair climb
test, and a 30-second chair stand test will be performed
[37]. Leg extension power (Nottingham Power Rig, Not-
tingham, UK) expressed as the product of force and vel-
ocity in a single-leg simultaneous hip and knee
extension will be measured. The force will be recorded
for each push (with 30 seconds rest between trials) until
the patients reach a plateau, defined as two successive
measurements below the highest measurement. A mini-
mum of six trials to minimize the learning effect and a
maximum of 12 trials to minimize fatigue will be con-
ducted and peak measurements in Watts obtained,
which is a methodology used frequently and illustrating
excellent reliability [38–40]. Maximal voluntary force
from the knee extensors and flexors will be measured bi-
laterally in isometric conditions with a handheld dyna-
mometer (Lafayette Manual Muscle Tester,
Loughborough, UK or MicroFET2, Hoggan Scientific,
LLC, Salt Lake City UT, USA). The patients will be
asked to exert a maximum voluntary isometric contrac-
tion lasting 5 seconds against the hand-held dynamom-
eter. Three trials of each test will be performed and the
peak value in Newtons will be the outcome score, which
is an approach that has illustrated excellent test-retest
reliability [41]. A 30-second break between each meas-
urement will be given.
Other outcomes Adverse events that may occurr during
the trial period will be identified by the patients (self-re-
ported) and by the physiotherapists supervising the inter-
ventions (observations). Adverse events are characterized
as occurring in the index knee or sites other than the
index knee and serious events are defined according to
the definitions from the U.S. Food and Drug Administra-
tion [42]. Non-serious adverse events are comprised of all
other occurring events. Participants are allowed to receive
other types of treatment at their own discretion. The other
types of treatment received during the trial period will be
self-reported. Other treatment is defined as treatments
that the patient had initiated because of the index knee
such as acupuncture, manual therapy, and surgery. Adher-
ence to interventions will be registered for both groups. In
the NEMEX-TJR and PNE group, the number of
attended exercise sessions and PNE sessions will be
recorded (i.e. number of sessions out of 24 exercises
sessions and two PNE sessions). In the PNE group,
the number of PNE sessions will be recorded (i.e.
number of sessions out of two possible sessions).
Statistics
The statistical analysis of the primary outcome will be
performed according to an intention-to-treat principle.
Statistical tests will be dependent of data distribution.
We expect data to be normally distributed, and
therefore, aim at using a repeated measures mixed
model with patients as random effect and time (baseline
and 3, 6, and 12months) and treatment arm (NEMEX-
TJR and PNE or PNE alone) as fixed effects, and with
adjustments for baseline imbalance. No imputation will
take place. Secondary outcomes and other endpoints will
be analyzed similarly to the primary outcome. The fre-
quency of adverse events will be compared between
groups at the 12-month follow-up using a Poisson re-
gression model with robust error variance. Categorical
outcomes will be analyzed using a Χ2 test, Fisher exact
test, or a Mann-Whitney U test as appropriate. A per-
protocol analysis will be performed for the primary out-
come, excluding patients who had poor adherence to the
intervention, defined as participating in less than 75% of
the exercise sessions and not attending both PNE ses-
sions, and excluding patients who undergo additional
surgery during follow-up. A 95% confidence interval (CI)
excluding 10 points or more in the KOOS4 score will be
interpreted as a lack of a clinically meaningful difference
between groups. P values and 95% CIs will be presented.
All authors will have access to the final anonymized trial
dataset.
Trial steering committee
See title page for members of the trial steering commit-
tee. All members participated in the conception of the
study design and procured funding. The principal inves-
tigator (JBL) is coordinating the ongoing trial. The trial
steering committee reviews the progress of the trial and
agrees the necessary changes in the protocol, if any.
Data collection and management
All obtained results will be collected using a test score
protocol or fulfilling questionnaires and thereafter, en-
tered into Excel (version 2016, Microsoft Corporation,
Redmond, WA, USA). From Excel, data will be trans-
ferred into SPSS version 25.0 (SPSS Inc., Chicago, IL,
USA) for statistical analyses. All collected test score pro-
tocols and questionnaires will be kept in a locked place
as back up. Anonymized study data in electronically for-
mat will be stored at an encrypted network. Access to
study data is restricted and cannot be accessed without
permission.
Audit
The North Denmark Region Committee on Health Re-
search Ethics selects a number of approved studies for
audit every year. These audits are independent from the
trial steering committee and possible study sponsors.
Publication
Results will be published regardless of outcome. Author-
ship will be determined based on the guidelines from
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the International Committee of Medical Journal Editors.
The authors do not have any publication restrictions.
Discussion
The aim of this trial is to evaluate the effects of a treat-
ment that could potentially relieve pain and improve
physical performance as well as provide education to as-
sist patients in handling their chronic pain and disability.
This is of definite importance since no other randomized
controlled trial has been conducted regarding exercise as
treatment for chronic pain after TKA [12, 13]. The trial
builds on the presence of sensitization in several studies
examining painful knee OA and chronic pain after TKA
[7, 43–46] and evaluates if it is possible to modulate
sensitization outcomes by using NEMEX-TJR in com-
bination with PNE.
The strengths of the trial are the use of rigorous
methods that include randomized allocation, blinding of
outcome assessors, and the use of clinical applicable in-
terventions. The trial interventions are conducted in
clinical settings, thereby enhancing potential future im-
plementation of the treatments in health care systems.
There are some potential limitations of the trial. Since
the patients have chronic pain, some may use pain medi-
cation. This could interfere with the assessment of pain.
In order to reduce possible bias from this, the use and
dosage of medication will be assessed, allowing the study
group to evaluate whether the use of pain medication in-
creased or declined during the trial. Chronic pain pa-
tients often have comorbidities or other painful
musculoskeletal disorders [47] that may influence how
they respond to the interventions. One way to avoid this
influence would be to sample a population of patients
with no other pain sites or comorbidities besides knee
pain following TKA. Such a homogeneous group would
not reflect real-life patients and therefore, the results
would not be generalizable. Due to their chronic pain
and disabilities, patients might decide to seek help or
other treatments during the trial. Patients who receive
PNE alone might be more interested in seeking other
treatments than the exercise group, which will already
be receiving additional treatment twice a week. If this
occurs, it might counterbalance the possible differences
between the groups. To avoid this bias, we will collect
data on other treatments received during the trial
period, which will allow us to evaluate whether this par-
ameter might have had an impact. Since the group re-
ceiving NEMEX-TJR in combination with PNE has 24
more sessions with the physiotherapist, there is an inher-
ent risk that part of the explanation for a possible larger
effect in this group will be due to the increased attention
that they receive alongside a stronger patient-practitioner
interaction [48]. Large contributions from contextual fac-
tors have been observed in treatment effects, although not
thoroughly studied in trials of exercise and education as
treatment of knee pain [49]. Finally, no process or eco-
nomic evaluation will be conducted within the present
trial. Such evaluations will be important to ease and justify
a more general implementation of the NEPNEP interven-
tion in TKA patients suffering from chronic pain.
Trial status
The trial is ongoing and is currently recruiting patients.
Recruitment was initiated on April 12, 2019 and is ex-
pected to be completed by the end of December 2021.
This protocol is based on protocol version 4.0 of the 16
August 2018. The trial was registered with Clinical-
Trials.gov (NCT03886259) on the 22 March 2019.
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1186/s13063-020-4126-5.
Additional file 1. SPIRIT 2013 Checklist for the NEPNEP trial.
Additional file 2. The TIDieR (Template for Intervention Description and
Replication) Checklist for the NEPNEP trial.
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